Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1

Conditions

Adenocarcinoma of Lung 2Mesothelioma, Malignant 1Lymphoma 1Lung Neoplasms 1Colonic Neoplasms 1

Interventions

Cisplatin 12Pemetrexed 6Radiotherapy 5Platinum 4Doxorubicin 41,2-diaminocyclohexaneplatinum II citrate 4cediranib 3Mitomycin 3Gemcitabine 3Decitabine 3pembrolizumab 2Vinorelbine 2SS1(dsFv)PE38 2Interferon-gamma 2Gene Expression Profiling 2Erlotinib Hydrochloride 2Depsipeptides 2Cyclophosphamide 2Celecoxib 2sargramostim 1rilotumumab 1ranpirnase 1methoxyamine 1entinostat 1decitabine and cedazuridine drug combination 1cixutumumab 1belinostat 1atezolizumab 1anetumab ravtansine 1alvocidib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Mesothelioma, Malignant × methoxyamine × Clear all
NCT02535312 2026-04-17

Methoxyamine, Cisplatin, and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors or Mesothelioma That Cannot Be Removed by Surgery or Mesothelioma That Is Refractory to Pemetrexed Disodium and Cisplatin or Carboplatin

National Cancer Institute (NCI)

Phase 1/2 Active not recruiting
30 enrolled 15 charts
Other solid neoplasmThoracic

Mesothelioma, Malignant

Data powered by HemOnc (CC BY 4.0) Colophon âš¡